Reducing Supply Risk in Cell & Gene Therapy Trials

Cell and gene therapy trials introduce a fundamentally different model for clinical supply management. Unlike traditional studies that rely on pooled inventory, these therapies often depend on patient-specific manufacturing processes where a single disruption can impact a treatment that cannot simply be replaced. As a result, supply risk is no longer defined by inventory levels alone. It is defined by the ability to coordinate patients, sites, manufacturing facilities, and logistics partners within tightly controlled timelines.
​
Success depends on maintaining visibility and control across every step of the vein-to-vein journey, from patient eligibility and manufacturing slot reservations to chain-of-identity tracking and final administration. When information is fragmented across systems, manual processes can introduce delays, miscommunication, and operational risk.

Organizations that connect clinical operations, manufacturing, and logistics through coordinated workflows are better positioned to improve oversight, reduce avoidable disruptions, and help ensure therapies reach patients safely and on schedule